Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

2005 • 5,383 citations

Cancer Statistics, 2006

2006 • 5,351 citations

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 • 4,992 citations

Estimating the world cancer burden: Globocan 2000

2001 • 3,781 citations

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

2003 • 2,874 citations

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

2003 • 2,522 citations

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

2004 • 1,709 citations

Tyrosine Kinases as Targets for Cancer Therapy

2005 • 1,365 citations

Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer

2003 • 1,248 citations

A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

1998 • 1,210 citations

Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.

1995 • 791 citations

Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

1999 • 707 citations

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

2005 • 483 citations

Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity.

1984 • 467 citations

Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer

2005 • 466 citations

Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.

1983 • 456 citations

Hepatocellular Carcinoma: The Need for Progress

2005 • 410 citations

Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

2006 • 393 citations

Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?

2006 • 259 citations

Phase II Trial of Cetuximab in Patients With Previously Treated Non–Small-Cell Lung Cancer

2006 • 185 citations

EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer

2005 • 160 citations

Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade.

2002 • 140 citations

Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas.

1997 • 135 citations

Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma.

1987 • 129 citations

Transforming growth factor-? and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma

1999 • 110 citations

Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma

1997 • 105 citations

Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: Relative expression of transforming growth factor-α and its receptor in the different areas of tumor

1995 • 75 citations

Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines.

1988 • 64 citations

Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: An immunohistochemical study

2001 • 64 citations

Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial

2006 • 63 citations

Absence of epidermal growth factor receptor exon 18–21 mutation in hepatocellular carcinoma

2004 • 48 citations

A phase II open-label study of OSI-774 (NSC 718781) in unresectable hepatocellular carcinoma

2005 • 17 citations

Efficacy of Cetuximab After Treatment with Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor—Based Chemotherapy in Metastatic Colorectal Cancer

2006 • 10 citations